ArticleOptimizing Clozapine Treatment Part IPhansalkar, Sachin MD; Osser, David N. MDEditor(s): Janicak, Philip G. MD Author Information Dr. Phansalkar is an Instructor in Psychiatry, Harvard Medical School, Boston, MA, and an Attending Psychiatrist, Taunton State Hospital, Taunton, MA; and Dr. Osser is an Associate Professor of Psychiatry at Harvard Medical School, Boston, MA, and Associate Medical Director, Taunton State Hospital, 60 Hodges Avenue Extension, Taunton, MA 02780; E-mail: [email protected]. The authors have disclosed that they have no significant relationships with or financial interests in any commercial organizations pertaining to this educational activity. The authors also have disclosed that the use of clozapine for treatment of schizophrenia in certain patients who may not have had appropriate courses of standard drug treatment as discussed in this article has not been approved by the U.S. Food and Drug Administration. All faculty and staff in a position to control the content of this CME activity have disclosed that they have no financial relationships with, or financial interests in, any commercial companies pertaining to this educational activity. Lippincott CME Institute, Inc., has identified and resolved all faculty and staff conflicts of interest regarding this educational activity. Psychopharm Review: January 2009 - Volume 44 - Issue 1 - p 1-7 doi: 10.1097/01.IDT.0000343379.44905.2f Buy CME Test Metrics © 2009 Lippincott Williams & Wilkins, Inc.